Biological DMARDs aren´t currently tested with the IMBG due that they are monoclonal antibodies with a larger molecular size, what hamper the passive diffusion process in the hydrogel through the IMBG channels to create a concentration gradient. An adaptation in the diffusion process is being developed to adjust IMBG to the physicochemical features of these compounds is currently ongoing. For the Rheumatoid Arthritis indication, we have added JAK inhibitors, which demonstrates that such adaptations to other products are possible.